Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of AHB-137 in Participants With Liver Dysfunction and Normal Liver Function
NCT07600788Phase 1Recruiting
- Sponsor
- AusperBio
- Start
- Jul 2026
- Primary completion
- May 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of AHB-137 in Chronic Hepatitis B (CHB) (4 arms), sponsored by AusperBio. Primary endpoints: Peak Concentration and Area Under the Curve from 0 to infinity. Started Jul 2026; status: recruiting.
02
Drugs
AHB-137
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07600788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600788.